РОЛЬ ДИАГНОСТИКИ АРИТМИЙ И НАРУШЕНИЙ ПРОВОДИМОСТИ, СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ В ПРОГНОЗЕ ПАЦИЕНТОВ С САРКОИДОЗОМ СЕРДЦА
Аннотация
Саркоидоз сердца – это хроническое воспалительное заболевание, проявляющееся неказеозными очаговыми гранулематозными поражениями сердца с подозрением на иммунопатологический ответ на неустановленный антигенный фактор у человека с генетической предрасположенностью. Известно, что саркоидоз сердца является второй по распространенности причиной смерти пациентов с саркоидозом во всем мире. Саркоидоз часто протекает как системное воспаление с поражением многих органов, хотя редко он может проявляться в изолированных формах. Вышеупомянутый специфический фенотип трудно диагностировать, поскольку он требует ряда других исключений, и при отсутствии лечения может прогрессировать до фиброза, а сердечная дисфункция в конечном итоге приводит к внезапной сердечной смерти, что побуждает исследователей и клиницистов модифицировать новые методы диагностики и тактику ведения. В зависимости от распространения и тяжести конкретного фенотипа заболевания, клиническая картина может варьироваться от бессимптомной формы до тяжелых фатальных сердечных проявлений, таких как декомпенсированная сердечная недостаточность, тяжелые формы желудочковой и предсердной аритмий, нарушения проводимости и внезапной смерти. Поэтому ранняя диагностика и своевременное начало лечебной тактики, включая иммуносупрессивные препараты, по-прежнему имеют решающее значение для борьбы с этим патологическим состоянием.
Литература
References
Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, Judson MA, Kron J, Mehta D, Cosedis Nielsen J, Patel AR, Ohe T, Raatikainen P, Soejima K. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11(7):1305-23. https://doi.org/10.1016/j.hrthm.2014.03.043.
Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, Oritsu M, Nukiwa T. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31(2):372-9. https://doi.org/10.1183/09031936.00075307.
Hillerdal G, Nöu E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis. 1984;130(1):29-32.
Korsten P, Tampe B, Konig MF, Nikiphorou E. Sarcoidosis and autoimmune diseases: differences, similarities and overlaps. Curr Opin Pulm Med. 2018;24(5):504-512. https://doi.org/10.1097/MCP.0000000000000500.
Huang H, Lu Z, Jiang C, Liu J, Wang Y, Xu Z. Imbalance between Th17 and regulatory T-Cells in sarcoidosis. Int J Mol Sci. 2013;14(11):21463-73. https://doi.org/10.3390/ijms141121463.
Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24(1):59-65. https://doi.org/10.1097/MOH.0000000000000301.
Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, Hendriks RW, Kleinjan A. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford). 2012;51(1):37-46. https://doi.org/10.1093/rheumatology/ker316.
Te HS, Perlman DM, Shenoy C, Steinberger DJ, Cogswell RJ, Roukoz H, Peterson EJ, Zhang L, Allen TL, Bhargava M. Clinical characteristics and organ system involvement in sarcoidosis: comparison of the University of Minnesota Cohort with other cohorts. BMC Pulm Med. 2020;20(1):155. https://doi.org/10.1186/s12890-020-01191-x.
Sweis N, Dominati A, Prasad S, Alnaimat F, Alawqati M, Rubinstein I, Caskey R. Tobacco smoking and sarcoidosis revisited-Evidence, mechanisms, and clinical implications: a narrative review. Curr Med Res Opin. 2025;41(5):901-916. https://doi.org/10.1080/03007995.2025.2495852.
Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB, Thomsen SF. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008;63(10):894-6. https://doi.org/10.1136/thx.2007.094060.
Segura AM, Radovancevic R, Demirozu ZT, Frazier OH, Buja LM. Granulomatous myocarditis in severe heart failure patients undergoing implantation of a left ventricular assist device. Cardiovasc Pathol. 2014;23(1):17-20. https://doi.org/10.1016/j.carpath.2013.06.005.
Philips B, Madhavan S, James CA, te Riele AS, Murray B, Tichnell C, Bhonsale A, Nazarian S, Judge DP, Calkins H, Tandri H, Cheng A. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014;7(2):230-6. https://doi.org/10.1161/CIRCEP.113.000932.
Roberts WC, Roberts CC, Ko JM, Filardo G, Capehart JE, Hall SA. Morphologic features of the recipient heart in patients having cardiac transplantation and analysis of the congruence or incongruence between the clinical and morphologic diagnoses. Medicine (Baltimore). 2014;93(5):211-235. https://doi.org/10.1097/MD.0000000000000038.
Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager H Jr, Johns CJ, Rabin DL, Rybicki BA, Cherniack R. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324-30. https://doi.org/10.1164/rccm.200402-249OC.
Rossides M, Grunewald J, Eklund A, Kullberg S, Di Giuseppe D, Askling J, Arkema EV. Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study. Eur Respir J. 2018;52(2):1800385. https://doi.org/10.1183/13993003.00385-2018.
Moller DR, Rybicki BA, Hamzeh NY, Montgomery CG, Chen ES, Drake W, Fontenot AP. Genetic, Immunologic, and Environmental Basis of Sarcoidosis. Ann Am Thorac Soc. 2017;14(Suppl. 6):S429-S436. https://doi.org/10.1513/AnnalsATS.201707-565OT.
Costabel U. Sarcoidosis: clinical update. Eur Respir J. 2001;18(32 suppl):56S-68S. https://doi.org/10.1183/09031936.01.18s320056.
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149-73.
Drent M, Crouser ED, Grunewald J. Challenges of Sarcoidosis and Its Management. N Engl J Med. 2021;385(11):1018-1032. https://doi.org/10.1056/NEJMra2101555.
Murtagh G, Laffin LJ, Patel KV, Patel AV, Bonham CA, Yu Z, Addetia K, El-Hangouche N, Maffesanti F, Mor-Avi V, Hogarth DK, Sweiss NJ, Beshai JF, Lang RM, Patel AR. Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Echocardiography. 2016;33(9):1344-52. https://doi.org/10.1111/echo.13281.
Wu Y, Lu Q, Liu Z, Wu J, He X, Yang Y, Li Y. Advances in imaging and artificial intelligence for precision diagnosis and biopsy guidance in prostate cancer. Front Oncol. 2025;15:1614891. https://doi.org/10.3389/fonc.2025.1614891.
Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging. 2015;16(6):634-41. https://doi.org/10.1093/ehjci/jeu294.
Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189(1):109-12. https://doi.org/10.1164/rccm.201309-1668LE.
Ishimaru S, Tsujino I, Sakaue S, Oyama N, Takei T, Tsukamoto E, Tamaki N, Nishimura M. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(3):234-5.
Suzuki T, Kanda T, Kubota S, Imai S, Murata K. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest. 1994;106(4):1021-4. https://doi.org/10.1378/chest.106.4.1021.
Chopra A, Kalkanis A, Judson MA. Biomarkers in sarcoidosis. Expert Rev Clin Immunol. 2016;12(11):1191-1208. https://doi.org/10.1080/1744666X.2016.1196135.
Fazelpour S, Sadek MM, Nery PB, Beanlands RS, Tzemos N, Toma M, Birnie DH. Corticosteroid and Immunosuppressant Therapy for Cardiac Sarcoidosis: A Systematic Review. J Am Heart Assoc. 2021;10(17):e021183. https://doi.org/10.1161/JAHA.121.021183.
Stievenart J, Le Guenno G, Ruivard M, Rieu V, André M, Grobost V. Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies. Eur Respir J. 2022;59(5):2100449. https://doi.org/10.1183/13993003.00449-2021.
Lamba A, Roston TM, Peltenburg PJ, Kallas D, Franciosi S, Lieve KVV, Kannankeril PJ, Horie M, Ohno S, Brugada R, Aiba T, Fischbach P, Knight L, Till J, Kwok SY, Probst V, Backhoff D, LaPage MJ, Batra AS, Drago F, Haugaa K, Krahn AD, Robyns T, Swan H, Tavacova T, et al. An international multicenter cohort study on implantable cardioverter-defibrillators for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2024;21(10):1767-1776. https://doi.org/10.1016/j.hrthm.2024.04.006.
Mohameden M, Vashisht P, Sharman T. Scleroderma and Primary Myocardial Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557686
Nordenswan HK, Pöyhönen P, Lehtonen J, Ekström K, Uusitalo V, Niemelä M, Vihinen T, Kaikkonen K, Haataja P, Kerola T, Rissanen TT, Alatalo A, Pietilä-Effati P, Kupari M. Incidence of Sudden Cardiac Death and Life-Threatening Arrhythmias in Clinically Manifest Cardiac Sarcoidosis With and Without Current Indications for an Implantable Cardioverter Defibrillator. Circulation. 2022;146(13):964-975. https://doi.org/10.1161/CIRCULATIONAHA.121.058120.
Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-e391. https://doi.org/10.1161/CIR.0000000000000549.
Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M, Prasad S, Koulouris N, Sfikakis P, Wells A, Gialafos E. Complementary Role of CMR to Conventional Screening in the Diagnosis and Prognosis of Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10(12):1437-1447. https://doi.org/10.1016/j.jcmg.2016.11.019.
Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M, Machac J, Teirstein A. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133(6):1426-1435. https://doi.org/10.1378/chest.07-2784.
Eurelings LEM, Miedema JR, Dalm VASH, van Daele PLA, van Hagen PM, van Laar JAM, Dik WA. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis. PLoS One. 2019;14(10):e0223897. https://doi.org/10.1371/journal.pone.0223897.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627-3639. https://doi.org/10.1093/eurheartj/ehad195.
